Research houses are Neutral on Jamjoom Pharma as Q3 profit climbs to SAR 106.7 million, with target prices averaging SAR 168.5 per share.

How did analysts view Jamjoom Pharma Q3 2025 financials?

JAMJOOM PHARMA(0.47%)

Research houses are Neutral on Jamjoom Pharma as Q3 profit climbs to SAR 106.7 million, with target prices averaging SAR 168.5 per share.

To Access this Content, Please Login Or Register

To Access this Content, Please Login or Subscribe

Most Read